RxDoctor Payments Data

Tarak Shah, MD

Nephrology · Greenville, SCNPI 1841618329

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (56.0%), food and beverage and education — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Calliditas Therapeutics US Inc. at 58.8% of the total. 2025 is the largest year on record at $6,270, more than ten times the $115 reported in 2020.

$8,717in general payments, 2019–2025

Across 161 payments — averaging $54.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Calliditas Therapeutics US Inc.$5K
  • Amgen$720
  • AstraZeneca$400
  • Outset Medical Inc$318
  • Novartis$294
  • Bayer$247
  • plus $2K from 19 others

What the payments were for

  • Consulting fees$4,88156%
  • Food & beverage$3,71943%
  • Education$1171%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,717 in reported general payments places this provider in the 85th percentile of 180 nephrology providers in South Carolina.

See all nephrology providers in South Carolina

Medicare billing

Part B allowed, 2024
$137,845
Medicare patients
464
Services billed
2,130

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin26$40,642
FarxigaDapagliflozin Propanediol23$32,070
Potassium Citrate ErPotassium Citrate12$1,378
Losartan Potassium100$792
Hydralazine Hcl55$758
Amlodipine Besylate113$524
Allopurinol54$387
Furosemide97$328
Diltiazem 24hr Er (Cd)Diltiazem Hcl15$323
Lisinopril47$145
Metoprolol Succinate15$112
Hydrochlorothiazide19$72
Spironolactone11$72
Carvedilol13$58

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$143$40,64226 claims
AstraZenecaFarxiga$400$32,07023 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 180 nephrology providers in South Carolina.

Other nephrology in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →